AxoGen (NASDAQ:AXGN) Shares Gap Down – Time to Sell?

22 Jan 2026, 20:41 by Danessa Lincoln · The Markets Daily

AxoGen, Inc. (NASDAQ:AXGN – Get Free Report)’s stock price gapped down before the market opened on Thursday . The stock had previously closed at $33.01, but opened at $32.10. AxoGen shares last traded at $32.2650, with a volume of 1,205,625 shares traded.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on AXGN shares. Weiss Ratings restated a “sell (e+)” rating on shares of AxoGen in a research report on Monday, December 29th. Lake Street Capital increased their price objective on AxoGen from $30.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, December 4th. Citigroup reaffirmed a “market outperform” rating on shares of AxoGen in a report on Thursday, October 30th. Canaccord Genuity Group increased their price target on shares of AxoGen from $27.00 to $37.00 and gave the stock a “buy” rating in a report on Friday, December 5th. Finally, Jefferies Financial Group boosted their price objective on shares of AxoGen from $29.00 to $36.00 and gave the company a “buy” rating in a research note on Thursday, December 4th. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, AxoGen currently has an average rating of “Moderate Buy” and an average price target of $35.56.

Read Our Latest Stock Analysis on AXGN

AxoGen Price Performance

The business’s fifty day moving average price is $30.24 and its 200-day moving average price is $21.15. The company has a market capitalization of $1.46 billion, a P/E ratio of -637.20 and a beta of 1.00. The company has a current ratio of 4.09, a quick ratio of 2.64 and a debt-to-equity ratio of 0.54.

AxoGen (NASDAQ:AXGN – Get Free Report) last released its quarterly earnings results on Wednesday, October 29th. The medical equipment provider reported $0.12 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.03. AxoGen had a negative return on equity of 1.90% and a negative net margin of 0.98%.The business had revenue of $60.08 million for the quarter, compared to the consensus estimate of $56.90 million. As a group, sell-side analysts predict that AxoGen, Inc. will post -0.29 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other AxoGen news, Director Paul Thomas sold 21,399 shares of the stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $29.61, for a total transaction of $633,624.39. Following the transaction, the director directly owned 13,528 shares in the company, valued at $400,564.08. This trade represents a 61.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Marc A. Began sold 9,278 shares of the business’s stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $31.21, for a total transaction of $289,566.38. Following the completion of the sale, the executive vice president owned 31,507 shares of the company’s stock, valued at approximately $983,333.47. The trade was a 22.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 399,759 shares of company stock valued at $11,371,779 over the last 90 days. Company insiders own 2.78% of the company’s stock.

Hedge Funds Weigh In On AxoGen

A number of large investors have recently bought and sold shares of AXGN. First Light Asset Management LLC raised its holdings in AxoGen by 28.2% during the 3rd quarter. First Light Asset Management LLC now owns 5,805,730 shares of the medical equipment provider’s stock valued at $103,574,000 after buying an additional 1,276,487 shares during the last quarter. Balyasny Asset Management L.P. boosted its holdings in shares of AxoGen by 183.9% during the second quarter. Balyasny Asset Management L.P. now owns 1,931,158 shares of the medical equipment provider’s stock worth $20,953,000 after purchasing an additional 1,250,968 shares during the period. Bessemer Group Inc. purchased a new stake in shares of AxoGen during the third quarter worth about $14,468,000. Wasatch Advisors LP increased its holdings in AxoGen by 85.1% during the 2nd quarter. Wasatch Advisors LP now owns 1,433,782 shares of the medical equipment provider’s stock valued at $15,557,000 after purchasing an additional 659,149 shares during the period. Finally, Brown Capital Management LLC bought a new position in AxoGen during the 3rd quarter valued at approximately $11,500,000. 80.29% of the stock is owned by hedge funds and other institutional investors.

AxoGen Company Profile

(Get Free Report)

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.